

SYMPHONY™ SIGNIFICANTLY IMPROVES DFU HEALING

Highlights

- A new Randomised Controlled Trial (RCT) found that adding Symphony™ to standard of care **substantially improved healing outcomes** for diabetic foot ulcers.
- The Diabetic Foot Ulcers (DFUs) that were treated with Symphony and standard of care **healed significantly faster**; and **were significantly more likely to completely close within 12 weeks**, than the DFUs that were only treated with standard of care.
- The RCT enrolled **challenging DFUs**, classified as Wagner grade 1 or 2.
- The findings provide high-quality clinical evidence supporting **Symphony's effectiveness** and are expected to support product differentiation, clinical adoption, and evolving US reimbursement requirements.

AROA is pleased to announce positive results from the prospective multicenter RCT for Symphony, recently published in *International Wound Journal*.

The RCT enrolled 143 patients across 10 US sites. The study treated challenging diabetic foot ulcers classified as Wagner Grade 1 or 2, ranging from superficial ulcers involving the full thickness of the skin (Grade 1) to deeper ulcers extending into ligaments, tendons, joint capsules, or deep fascia (Grade 2).

Patients were randomly assigned into either the Symphony arm (where they received weekly treatment with Symphony plus standard of care) (SOC) or the standard of care only arm (where they received standard of care only). Patients were treated for up to 12 weeks or until complete wound closure.

The study found:

- **55%** of DFUs in the Symphony arm achieved complete wound closure within 12 weeks, compared with **35%** in the SOC-only arm ($p=0.039$)
- Mean time to complete wound closure was **65.4 days** for DFUs in the Symphony arm, compared with **73.2 days** for DFUs in the SOC-only arm—a reduction of **7.8 days** ($p=0.041$).

Lead Investigator, Dr David Armstrong says: "New technologies and high-quality randomised clinical evidence are essential if we are to continue improving outcomes for patients with diabetic foot ulcers. The Symphony trial demonstrates that combining a novel extracellular matrix bioscaffold with high molecular weight hyaluronic acid can significantly improve wound healing when added to good standard of care. Studies like this help clinicians make informed treatment decisions based on robust evidence."

AROA CEO Brian Ward says: "This is a major milestone for Symphony. The study delivered clear, statistically significant results: adding Symphony to standard of care when treating DFUs increased the incidence of complete wound closure at 12 weeks by 55% and reduced the mean healing time by 7.8 days."

The multicentre design and involvement of recognised key opinion leaders strengthen the evidence’s credibility and clinical relevance. Amid growing demand from clinicians, payors, and reimbursement authorities for robust RCT data, this publication places Symphony among a small group of CAMPs with Level I effectiveness data, strengthening its differentiation and commercial value proposition.”

The full study, titled ***A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Full Thickness Wounds of the Foot in People with Diabetes: A Randomized Controlled Trial*** is available, [here](#)

About Symphony™

Symphony is AROA’s Cellular, Acellular and Matrix-like Product (‘CAMP’, or ‘skin substitute’) product combining AROA ECM™ with high molecular weight hyaluronic acid (HMWHA). It is designed to treat hard to heal wounds such as DFUs and venous leg ulcers.

HMWHA is a naturally occurring polymer with anti-inflammatory properties and the ability to retain approximately 1,000 times its weight in water, making it well suited to chronic wounds with persistent inflammation and moisture imbalance.

While CAMPs are commonly used to treat DFUs, AROA understands Symphony is the only commercially available product incorporating HMWHA.

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contact

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com